1.03
+0(+0.00%)
Currency In USD
| Previous Close | 1.03 |
| Open | 1.02 |
| Day High | 1.03 |
| Day Low | 1.01 |
| 52-Week High | 1.29 |
| 52-Week Low | 0.52 |
| Volume | 1.35M |
| Average Volume | 4.3M |
| Market Cap | 321.67M |
| PE | -5.42 |
| EPS | -0.19 |
| Moving Average 50 Days | 1.03 |
| Moving Average 200 Days | 0.84 |
| Change | 0 |
If you invested $1000 in Ocugen, Inc. (OCGN) 10 years ago, it would be worth $2.77 as of September 09, 2025 at a share price of $1.03. Whereas If you bought $1000 worth of Ocugen, Inc. (OCGN) shares 5 years ago, it would be worth $3,029.41 as of September 09, 2025 at a share price of $1.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
GlobeNewswire Inc.
Sep 02, 2025 11:02 AM GMT
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executi
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
GlobeNewswire Inc.
Aug 13, 2025 10:27 AM GMT
MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products for Human Use
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
GlobeNewswire Inc.
Aug 12, 2025 7:45 PM GMT
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered dire